Coverage
Filings
| Filing | Date |
|---|---|
| Nucala approved in Japan for use in CRSwNP | 28 Aug 2024 |
| SENKU Designation for Bepirovirsen in Japan | 28 Aug 2024 |
| Director/PDMR Shareholding | 21 Aug 2024 |
| B7-H3 ADC US FDA Breakthrough Therapy Designation | 20 Aug 2024 |
| Director/PDMR Shareholding | 20 Aug 2024 |
| Statement: Zantac (ranitidine) litigation | 16 Aug 2024 |
| Director/PDMR Shareholding | 12 Aug 2024 |
| Statement: Zantac (ranitidine) litigation |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 6 Aug 2024 |
| FDA Expands Jemperli Approval | 2 Aug 2024 |
| Total Voting Rights | 1 Aug 2024 |
| 2nd Quarter Results | 31 Jul 2024 |
| CHMP positive opinion on Arexvy for 50-59 at risk | 29 Jul 2024 |